Current Status
Not Enrolled
Get Started

Essentials of Residual Risk Video Series

If you are interested in earning Continuing Medical Education Credit  (CME) hit the To Start Button above and register.  If not continue to the course options below.

CME credit will open on August 31, 2021 and expire on August 31, 2022.  The final exam, with a passing score of 70%, is required to claim CME credit.  Please note: The practice tests associated with each video are not required to claim CME.  However, the questions are based on the Final Exam, so it is recommended that these be taken.


Once completing the Evaluation and achieving a passing score the Final Exam, your CME certificate will be available for download.  If you have any questions, please use the contact form at

Pre-activity information

NAFLD/NASH and ASCVD Connection: Final Messages

Patient Identification and Risk Stratification

ASCVD and NAFLD/NASH: the Background of the Connection

Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?

Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?

Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares

Parte 3, Sessão A – Uma hierarquia de abordagens de tratamento com base na gravidade para o paciente DM2 com DCVA

Parte 2 – Combatendo a aterosclerose: avaliando o risco CV para o paciente com DM2

Parte 1 – A história na batalha da insulina e glucagon

Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease

Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD

Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient

Part 1: The History in the Battle of Insulin and Glucagon

Modera resumen de los mensajes claves de las conferencias – Maria Cristina Izar (Brasil)

Discusión Foro 4 – Panelist Roopa Mehta (Mexico)

Nuevas terapias para la HF grave – Paola Varleta (Chile)

Eficacia y seguridad de Lomitapida en HF homocigota – Dirk Blom (SudAfrica)

Inhibidores PCSK9 en la HF grave – Maria Cristina Izar (Brasil)

« » page 1 / 13

Course Content

Available Now

Course Content

Expand All
Available Now